Recruiting

Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation

This observational study will assess the long-term effectiveness of the RDN procedure for lowering blood pressure in Medicare patients with uncontrolled hypertension. This research will be conducted using de-identified electronic health records (EHR) and administrative health insurance claims data. Patients are enrolled through the submission of claims or encounter data to CMS.

ClinicalTrials.gov IDNCT07174622

PhaseNot Applicable

Enrollment1000

SponsorMedtronic Vascular

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Hypertension, Cardiovascular Diseases, Vascular Diseases

About this study

Interventions

Device: Renal Denervation (Symplicity Spyral™) — Symplicity Spyral™ multi-electrode renal denervation system

Primary outcomes

Change in Office Systolic Blood Pressure (OSBP) (2 years)

Eligibility information

Inclusion Criteria: * Enrolled in a Medicare plan * Diagnosis of uncontrolled hypertension * On a stable regimen of antihypertensive therapy Exclusion Criteria: * A prior RDN procedure * Diagnosis of secondary hypertension * Any condition for which RDN is contraindicated

Study locations

Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.